Amylose à transthyrétine (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amylose à transthyrétine" in French language version.

refsWebsite

Global rank French rank

10sciencedirect.com

149^th place

80^th place

5nejm.org

2,374^th place

298^th place

5ahajournals.org

3,608^th place

659^th place

4wiley.com

222^nd place

129^th place

4springer.com

274^th place

223^rd place

3tandfonline.com

507^th place

420^th place

2oup.com

485^th place

416^th place

1bmj.com

1,226^th place

347^th place

1lww.com

2,769^th place

931^st place

1has-sante.fr

9,562^nd place

535^th place

1jamanetwork.com

2,650^th place

689^th place

ahajournals.org

bmj.com

jcp.bmj.com

Gilbertson JA, Theis JD, Vrana JA et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue, J Clin Pathol, 2015;68:314–317

has-sante.fr

[PDF] Vyndaqel 20 mg, capsules molles - Avis (commission de la transparence)

jamanetwork.com

Berk JL, Suhr OB, Obici L et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial, JAMA, 2013;310:2658-2667

lww.com

journals.lww.com

Ericzon BG, Wilczek HE, Larsson M et al. Liver Transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?, Transplantation, 2015;99:1847–1854

nejm.org

Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med, 2018;379:1007-1016
Gillmore JD, Judge DP, Cappelli F et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy, N Engl J Med, 2024;390:132-142
Adams D, Gonzalez-Duarte A, O’Riordan WD et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis, N Engl J Med, 2018; 379:11-21
Benson MD, Waddington-Cruz M, Berk JL et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis, N Engl J Med, 2018;379:22-31
Gillmore JD, Gane E, Taubel J et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis, N Engl J Med, 2021;385:493-502

oup.com

academic.oup.com

González-López E, Gagliardi C, Dominguez F et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths, Eur Heart J, 2017;38:1895–1904
Ioannou A, Massa P, Patel RK et al. Conventional heart failure therapy in cardiac ATTR amyloidosis, Eur Heart J, 2023;44:2893–2907

sciencedirect.com

Crotty TB, Li CY, Edwards WD et al. Amyloidosis and endomyocardial biopsy: Correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases, Cardiovasc Pathol, 1995;4:39–42
Gertz MA, Benson MD, Dyck P et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis, J Am Coll Cardiol, 2015;66:2451-2466
Sperry BW, Reyes BA, Ikram A et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release, J Am Coll Cardiol, 2018:72:2040-2050
Westin O, Fosbøl EL, Maurer MS et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome, J Am Coll Cardiol, 2022;80:967-977
Maurer MS, Hanna M, Grogan M et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey), J Am Coll Cardiol, 2016;68:161–172
Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy, J Am Coll Cardiol, 2008;51:1022–1030
Dungu JN, Valencia O, Pinney JH et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis, J Am Coll Cardiol Img, 2014;7:133–142
Fine NM, Arruda-Olson AM, Dispenzieri A et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis, Am J Cardiol, 2014;113:1723–1727
Kittleson MM, Ruberg FL, Ambardekar AV et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee, J Am Coll Cardiol, 2023;81:1076–1126
Tojo K, Sekijima Y, Kelly JW et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis, Neurosci Res, 2006;56:441–449

springer.com

link.springer.com

Rapezzi C, Quarta CC, Guidalotti PL et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy, Eur J Nucl Med Mol Imaging, 2011;38:470–478
Aljaroudi WA, Desai MY, Tang WH et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques, J Nucl Cardiol, 2014;21:271–283
Scott LJ, Tafamidis: a review of its use in familial amyloid polyneuropathy, Drugs, 2014;74:1371–1378
Kristen AV, Lehrke S, Buss S et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report, Clin Res Cardiol, 2012;101:805–813

tandfonline.com

Coelho T, Maurer MS, Suhr OB, THAOS: The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis, Curr Med Res Opin, 2013;29:63–76
Tanskanen M, Peuralinna T, Polvikoski T et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study, Ann Med, 2008;40:232–239
Lobato L, Beirão I, Silva M et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors, Amyloid, 2004;11:27–37

wiley.com

onlinelibrary.wiley.com

Cappelli f, Baldasseroni s, Bergesio F et al. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis, Clin Cardiol, 2015;38:69–75
Garcia-Pavia P, Rapezzi C, Adler Y et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases, Eur J Heart Fail, 2021;23:512–526
Davis MK, Kale P, Liedtke M et al. (http://onlinelibrary.wiley.com/doi/10.1111/ajt.13025/abstract Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era], Am J Transplant, 2015;15:650–658
Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy, Eur J Neurol, 2013;20:1539-1545

Amylose à transthyrétine (French Wikipedia)

ahajournals.org

circ.ahajournals.org

ahajournals.org

circheartfailure.ahajournals.org

bmj.com

jcp.bmj.com

has-sante.fr

jamanetwork.com

lww.com

journals.lww.com

nejm.org

oup.com

academic.oup.com

sciencedirect.com

springer.com

link.springer.com

tandfonline.com

wiley.com

onlinelibrary.wiley.com